Bone mineral density in well‐differentiated thyroid cancer patients treated with suppressive thyroxine: A systematic overview of the literature
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: The effects of subclinical hyperthyroidism on bone mineral density (BMD) induced by suppressive thyroxine therapy in patients with well‐differentiated thyroid cancer (WDTC) remains unclear. An overview of the current literature was undertaken to evaluate studies to date. Methods: A systematic medline search yielded a total of 11 studies appropriate for review which included premenopausal women, postmenopausal women, and men on suppressive thyroxine post thyroidectomy for WDTC. Main outcome measures were bone mineral density and bone turnover markers. Conclusions: Although studies were limited by small numbers and varying degrees of control for confounding variables, results suggested no significant change in bone mineral density for premenopausal women or men. Findings for postmenopausal women remain unclear with two of the best controlled studies reporting opposing results. Further studies for this population are recommended to help guide clinical practice. J. Surg. Oncol. 2002;79:62–70. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faber, J., & Galløe, A. M. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1300350 · Cited by 377
Jódar, E., Begoña López, M., García, L., Rigopoulou, D., Martínez, G., & Hawkins, F. (1998) · Osteoporosis International · doi:10.1007/s001980050069 · Cited by 59
Cited by
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418
“In a recent overview (494), it was found that there was no change or only a small decrease in BMD as a result of long-term TSH suppressive therapy (mean, 7.”
BackgroundRoberts, C. G., & Ladenson, P. W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15696-1 · Cited by 567
Role of Thyroid Hormones in Skeletal Development and Bone Maintenance
Bassett, J. H. D., & Williams, G. R. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1106 · Cited by 540
Biondi, B., & Cooper, D. S. (2010) · Thyroid · doi:10.1089/thy.2009.0311 · Cited by 286
“…dysfunction (61–63); The presence of thyroxine-related adrenergic signs and symptoms (51,52,54,61); Cigarette smoking; The presence of cardiovascular risk factors (38); Perimenopausal women, because of the potential risk of osteoporosis (97,98); Osteopenia (38); Risk factors for osteoporosis (38).”
Thyroid diseases and bone health
Williams, G. R., & Bassett, J. H. D. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0753-4 · Cited by 276
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
Wang, L. Y., Smith, A. W., Palmer, F. L., Tuttle, R. M., Mahrous, A., Nixon, I. J., Patel, S. G., Ganly, I., Fagin, J. A., & Boucai, L. (2015) · Thyroid · doi:10.1089/thy.2014.0287 · Cited by 161
“Two recent reviews on the effects of TSH suppression in DTC concluded that postmenopausal women were at increased risk of bone loss when TSH was suppressed, but the effect of hyperthyroidism on premenopausal women and men was conflicting (31,32).”
The skeletal consequences of thyrotoxicosis
Nicholls, J. J., Brassill, M. J., Williams, G. R., & Bassett, J. H. D. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0059 · Cited by 138
Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy
Ito, M., Miyauchi, A., Hisakado, M., Yoshioka, W., Ide, A., Kudo, T., Nishihara, E., Kihara, M., Ito, Y., Kobayashi, K., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0426 · Cited by 91
Thyroid Hormone Suppression Therapy
Biondi, B., & Cooper, D. S. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.10.008 · Cited by 81
Schneider, R., Schneider, M., Reiners, C., & Schneider, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2570 · Cited by 48
Yoon, B.-H., Lee, Y., Oh, H. J., Kim, S. H., & Lee, Y.-K. (2019) · Journal of Bone Metabolism · doi:10.11005/jbm.2019.26.1.51 · Cited by 46
Papi, G., Pearce, E. N., Braverman, L. E., Betterle, C., & Roti, E. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.01.004 · Cited by 39
(2007) · PubMed · Cited by 39
Kwak, D., Ha, J., Won, Y., Kwon, Y., & Park, S. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043007 · Cited by 34
Shin, D. W., Suh, B., Lim, H., Yun, J. M., Song, S. O., & Park, Y. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3407 · Cited by 32
Heemstra, K. A., Smit, J. W. A., Eustatia‐Rutten, C. F. A., Heijboer, A. C., Frölich, M., Romijn, J. A., & Corssmit, E. P. M. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02660.x · Cited by 31
“This condition affects several organ systems, including bone ( 20-23 ) and the cardiovascular system (24-28).”
BackgroundEffects of Thyrotropin Suppression on Bone Health in Menopausal Women with Total Thyroidectomy
Kim, E. H., Jeon, Y. K., Pak, K., Kim, I.-J., Kim, S.-J., Shin, S., Kim, B. H., Kim, S. S., Lee, B.-J., Lee, J.-G., et al. (2019) · Journal of Bone Metabolism · doi:10.11005/jbm.2019.26.1.31 · Cited by 26
Thyroxine Therapy in Euthyroid Patients Does Not Affect Body Composition or Muscular Function
Dubois, S., Abraham, P., Rohmer, V., Rodien, P., Audran, M., Dumas, J.-F., & Ritz, P. (2008) · Thyroid · doi:10.1089/thy.2007.0037 · Cited by 24
Metadata
- Authors
- Quan, M. L., Pasieka, J. L., & Rorstad, O.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2001-12-19
- Volume
- 79
- Issue
- 1
- Pages
- 62-70
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W2081847060
- Cited by
- 75
- References
- 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.